KRRO
Korro Bio, Inc.
Price Chart
Latest Quote
$12.23
-1.54 (-11.18%)
Current Price
| Previous Close | $13.77 |
| Open | $13.56 |
| Day High | $13.57 |
| Day Low | $12.18 |
| Volume | 105,025 |
Stock Information
| Shares Outstanding | 14.42M |
| Total Debt | $42.88M |
| Cash Equivalents | $113.97M |
| Revenue | $3.84M |
| Net Income | $-113.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $175.52M |
| EPS (TTM) | $-11.68 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $127.51M |
| Sales | $3.84M |
| Income | $-113.50M |
| Book/sh | $8.29 |
| Cash/sh | $7.90 |
| Employees | 49 |
Financial Ratios
| Quick Ratio | 7.71 |
| Current Ratio | 8.13 |
| Debt/Eq | 35.85 |
Returns & Margins
| ROA | -26.81% |
| ROE | -87.78% |
| Operating Margin | -2154.03% |
Ownership
| Insider Ownership | 0.93% |
| Institutional Ownership | 96.88% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.41 |
| P/S | 45.69 |
| P/B | 1.47 |
Analyst Data
| Recommendation | none |
| Target Price | $20.00 |
Technical Indicators
| SMA20 | $11.89 |
| SMA50 | $12.20 |
| SMA200 | $17.38 |
| RSI | 55.78 |
| ATR | 1.2672 |
| Shares Float | 9.20M |
| Short Float | 9.85% |
| Short Ratio | 9.87 |
| Volatility | 2.10 |
| Rel Volume | 1.07 |
Performance History
| Week | +10.14% |
| Month | -1.30% |
| Quarter | +11.45% |
| 6 Months | +48.23% |
| YTD | +51.18% |
| Year | -4.10% |
| 3 Years | -31.24% |
| 5 Years | -97.60% |
| 10 Years | -98.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $12.17 | 240,498 |
| 2026-06-24 | $13.77 | 448,900 |
| 2026-06-23 | $13.71 | 479,600 |
| 2026-06-22 | $13.90 | 378,200 |
| 2026-06-18 | $12.99 | 736,200 |
| 2026-06-17 | $11.05 | 143,400 |
| 2026-06-16 | $10.66 | 221,500 |
| 2026-06-15 | $11.66 | 244,800 |
| 2026-06-12 | $11.61 | 315,500 |
| 2026-06-11 | $10.53 | 83,000 |
| 2026-06-10 | $10.59 | 91,700 |
| 2026-06-09 | $10.94 | 116,100 |
| 2026-06-08 | $10.59 | 115,100 |
| 2026-06-05 | $10.72 | 187,700 |
| 2026-06-04 | $11.18 | 101,400 |
| 2026-06-03 | $11.08 | 131,200 |
| 2026-06-02 | $11.00 | 156,700 |
| 2026-06-01 | $12.93 | 60,800 |
| 2026-05-29 | $13.41 | 118,200 |
| 2026-05-28 | $13.40 | 122,300 |
| 2026-05-27 | $13.76 | 204,700 |
| 2026-05-26 | $12.33 | 107,300 |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
đ° Latest News
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-19T12:06:00Z
One Korro Bio Insider Raised Stake By 19% In Previous Year
Simply Wall St. âĸ 2026-06-11T11:38:27Z
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Zacks âĸ 2026-04-28T16:00:05Z
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?
MarketBeat âĸ 2026-04-06T19:44:00Z
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-12T23:20:01Z
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
Zacks âĸ 2026-03-10T10:09:00Z
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates
Zacks âĸ 2026-02-26T17:15:04Z
We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully
Simply Wall St. âĸ 2026-02-13T11:11:33Z
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)
Insider Monkey âĸ 2026-02-02T14:53:32Z
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
Zacks âĸ 2026-01-30T12:35:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $6,392,000 | $2,271,000 | $0 | $0 |
| Operating Revenue | $6,392,000 | $2,271,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $93,734,000 | $94,181,000 | $84,534,000 | $58,998,000 |
| Other Income Expense | $-29,281,000 | $8,470,000 | $3,389,000 | $976,000 |
| Other Non Operating Income Expenses | $5,232,000 | $8,470,000 | $3,389,000 | $976,000 |
| Operating Expense | $93,734,000 | $94,181,000 | $84,534,000 | $58,998,000 |
| General And Administrative Expense | $28,159,000 | $30,545,000 | $27,284,000 | $16,797,000 |
| Interest Expense | - | - | - | $118,000 |
| Net Non Operating Interest Income Expense | - | - | - | $829,000 |
| Interest Expense Non Operating | - | - | - | $118,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Normalized Income | $-89,994,730 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Net Income From Continuing And Discontinued Operation | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Total Operating Income As Reported | $-121,855,000 | $-91,910,000 | $-84,534,000 | $-58,998,000 |
| Net Income Common Stockholders | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Net Income | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Net Income Including Noncontrolling Interests | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Net Income Continuous Operations | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Pretax Income | $-116,623,000 | $-83,440,000 | $-81,145,000 | $-58,022,000 |
| Special Income Charges | $-34,513,000 | $0 | - | - |
| Operating Income | $-87,342,000 | $-91,910,000 | $-84,534,000 | $-58,998,000 |
| Net Interest Income | - | - | - | $829,000 |
| Interest Income | - | - | - | $947,000 |
| Interest Income Non Operating | - | - | - | $947,000 |
| Per Share | ||||
| Diluted EPS | $-12.48 | $-9.37 | $-53.08 | $-7.25 |
| Basic EPS | $-12.48 | $-9.37 | $-53.08 | $-7.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $-7,247,730 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-48,549,000 | $-88,345,000 | $-80,904,000 | $-56,487,000 |
| Total Unusual Items | $-34,513,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-34,513,000 | $0 | - | - |
| Reconciled Depreciation | $4,280,000 | $3,565,000 | $3,630,000 | $2,511,000 |
| EBITDA (Bullshit earnings) | $-83,062,000 | $-88,345,000 | $-80,904,000 | $-56,487,000 |
| EBIT | $-87,342,000 | $-91,910,000 | $-84,534,000 | $-58,998,000 |
| Diluted Average Shares | $9,395,402 | $8,920,561 | $1,529,321 | $8,001,283 |
| Basic Average Shares | $9,395,402 | $8,920,561 | $1,529,321 | $8,001,283 |
| Diluted NI Availto Com Stockholders | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Tax Provision | $637,000 | $141,000 | $27,000 | $10,000 |
| Impairment Of Capital Assets | $30,886,000 | $0 | - | - |
| Restructuring And Mergern Acquisition | $3,627,000 | $0 | - | - |
| Research And Development | $65,575,000 | $63,636,000 | $57,250,000 | $42,201,000 |
| Selling General And Administration | $28,159,000 | $30,545,000 | $27,284,000 | $16,797,000 |
| Other Gand A | $13,765,000 | $17,385,000 | $13,841,000 | $7,827,000 |
| Salaries And Wages | $14,394,000 | $13,160,000 | $13,443,000 | $8,970,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $51,439,000 | $160,415,000 | $169,911,000 | $-99,031,000 |
| Total Assets | $113,506,000 | $226,240,000 | $221,663,000 | $73,742,000 |
| Total Non Current Assets | $31,134,000 | $94,708,000 | $48,935,000 | $16,659,000 |
| Other Non Current Assets | $4,881,000 | $6,203,000 | $6,120,000 | $4,769,000 |
| Investmentin Financial Assets | $10,031,000 | $36,959,000 | $0 | - |
| Current Assets | $82,372,000 | $131,532,000 | $172,728,000 | $57,083,000 |
| Other Current Assets | $6,247,000 | $3,741,000 | $3,015,000 | $1,232,000 |
| Receivables | $969,000 | $1,696,000 | $0 | - |
| Accounts Receivable | $969,000 | $1,696,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $75,156,000 | $126,095,000 | $166,150,000 | $55,248,000 |
| Cash And Cash Equivalents | $21,824,000 | $55,643,000 | $166,150,000 | $36,333,000 |
| Restricted Cash | - | $0 | $3,563,000 | $603,000 |
| Debt | ||||
| Total Debt | $43,486,000 | $44,765,000 | $33,207,000 | $3,130,000 |
| Long Term Debt And Capital Lease Obligation | $40,814,000 | $43,481,000 | $31,216,000 | $209,000 |
| Current Debt And Capital Lease Obligation | $2,672,000 | $1,284,000 | $1,991,000 | $2,921,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $62,067,000 | $65,825,000 | $51,752,000 | $172,773,000 |
| Total Non Current Liabilities Net Minority Interest | $50,130,000 | $50,865,000 | $32,269,000 | $164,072,000 |
| Other Non Current Liabilities | $1,481,000 | $1,472,000 | $1,053,000 | - |
| Non Current Deferred Liabilities | $7,835,000 | $5,912,000 | $0 | $0 |
| Current Liabilities | $11,937,000 | $14,960,000 | $19,483,000 | $8,701,000 |
| Other Current Liabilities | $70,000 | $277,000 | $842,000 | $207,000 |
| Current Deferred Liabilities | $0 | $3,513,000 | $0 | $0 |
| Payables And Accrued Expenses | $5,153,000 | $6,111,000 | $8,754,000 | $2,949,000 |
| Payables | $1,651,000 | $3,992,000 | $7,280,000 | $2,605,000 |
| Accounts Payable | $1,651,000 | $3,992,000 | $7,280,000 | $2,605,000 |
| Equity | ||||
| Common Stock Equity | $51,439,000 | $160,415,000 | $169,911,000 | $-99,031,000 |
| Total Equity Gross Minority Interest | $51,439,000 | $160,415,000 | $169,911,000 | $-99,031,000 |
| Stockholders Equity | $51,439,000 | $160,415,000 | $169,911,000 | $-99,031,000 |
| Gains Losses Not Affecting Retained Earnings | $212,000 | $268,000 | $0 | $-5,000 |
| Other Equity Adjustments | $212,000 | $268,000 | - | $-5,000 |
| Retained Earnings | $-383,846,000 | $-266,586,000 | $-183,005,000 | $-101,833,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $163,863,000 |
| Other | ||||
| Ordinary Shares Number | $9,417,295 | $9,377,259 | $8,016,516 | $8,001,283 |
| Share Issued | $9,417,295 | $9,377,259 | $8,016,516 | $8,001,283 |
| Tangible Book Value | $51,439,000 | $160,415,000 | $169,911,000 | $-99,031,000 |
| Invested Capital | $51,439,000 | $160,415,000 | $169,911,000 | $-99,031,000 |
| Working Capital | $70,435,000 | $116,572,000 | $153,245,000 | $48,382,000 |
| Capital Lease Obligations | $43,486,000 | $44,765,000 | $33,207,000 | $3,130,000 |
| Total Capitalization | $51,439,000 | $160,415,000 | $169,911,000 | $-99,031,000 |
| Additional Paid In Capital | $435,064,000 | $426,724,000 | $352,908,000 | $2,807,000 |
| Capital Stock | $9,000 | $9,000 | $8,000 | $0 |
| Common Stock | $9,000 | $9,000 | $8,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $7,835,000 | $5,912,000 | $0 | - |
| Long Term Capital Lease Obligation | $40,814,000 | $43,481,000 | $31,216,000 | $209,000 |
| Current Deferred Revenue | $0 | $3,513,000 | $0 | - |
| Current Capital Lease Obligation | $2,672,000 | $1,284,000 | $1,991,000 | $2,921,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,042,000 | $3,775,000 | $7,896,000 | $2,624,000 |
| Current Accrued Expenses | $3,502,000 | $2,119,000 | $1,474,000 | $344,000 |
| Investments And Advances | $10,031,000 | $36,959,000 | $0 | - |
| Available For Sale Securities | $10,031,000 | $36,959,000 | - | - |
| Net PPE | $16,222,000 | $51,546,000 | $42,815,000 | $11,890,000 |
| Accumulated Depreciation | $-10,569,000 | $-7,328,000 | $-7,842,000 | $-4,255,000 |
| Gross PPE | $26,791,000 | $58,874,000 | $50,657,000 | $16,145,000 |
| Leases | $9,681,000 | $22,438,000 | $3,356,000 | $2,941,000 |
| Construction In Progress | $0 | $107,000 | $8,242,000 | $2,049,000 |
| Other Properties | $16,370,000 | $35,167,000 | $38,337,000 | $10,465,000 |
| Machinery Furniture Equipment | $740,000 | $1,162,000 | $722,000 | $690,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $53,332,000 | $70,452,000 | $0 | $18,915,000 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-79,079,000 | $-77,976,000 | $-75,119,000 | $-58,857,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-78,561,000 | $-60,074,000 | $-67,283,000 | $-53,645,000 |
| Cash Flow From Continuing Operating Activities | $-78,561,000 | $-60,074,000 | $-67,283,000 | $-53,645,000 |
| Operating Gains Losses | $63,000 | $357,000 | $65,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-518,000 | $-17,902,000 | $-7,836,000 | $-5,212,000 |
| Investing Cash Flow | $43,993,000 | $-123,347,000 | $11,164,000 | $11,060,000 |
| Cash Flow From Continuing Investing Activities | $43,993,000 | $-123,347,000 | $11,164,000 | $11,060,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $67,385,000 | $162,708,000 | $0 |
| Financing Cash Flow | $685,000 | $69,355,000 | $187,761,000 | $18,000 |
| Cash Flow From Continuing Financing Activities | $685,000 | $69,355,000 | $187,761,000 | $18,000 |
| Net Common Stock Issuance | $0 | $67,385,000 | $117,250,000 | $0 |
| Common Stock Issuance | $0 | $67,385,000 | $117,250,000 | $0 |
| Net Preferred Stock Issuance | - | $0 | $45,458,000 | $0 |
| Preferred Stock Issuance | - | $0 | $45,458,000 | $0 |
| Net Other Financing Charges | - | - | $24,351,000 | $-44,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $1,000 | $141,000 | $27,000 | $11,000 |
| End Cash Position | $25,230,000 | $59,049,000 | $173,119,000 | $41,477,000 |
| Beginning Cash Position | $59,049,000 | $173,119,000 | $41,477,000 | $84,044,000 |
| Effect Of Exchange Rate Changes | $64,000 | $-4,000 | $0 | - |
| Changes In Cash | $-33,883,000 | $-114,066,000 | $131,642,000 | $-42,567,000 |
| Proceeds From Stock Option Exercised | $685,000 | $1,970,000 | $702,000 | $62,000 |
| Net Investment Purchase And Sale | $44,511,000 | $-105,445,000 | $19,000,000 | $16,272,000 |
| Sale Of Investment | $70,700,000 | $40,900,000 | $19,000,000 | $53,485,000 |
| Purchase Of Investment | $-26,189,000 | $-146,345,000 | $0 | $-37,213,000 |
| Net PPE Purchase And Sale | $-518,000 | $-17,902,000 | $-7,836,000 | $-5,212,000 |
| Purchase Of PPE | $-518,000 | $-17,902,000 | $-7,836,000 | $-5,212,000 |
| Change In Working Capital | $-4,426,000 | $13,591,000 | $4,283,000 | $-633,000 |
| Change In Other Working Capital | $-1,590,000 | $9,425,000 | - | - |
| Change In Other Current Liabilities | $-1,279,000 | $11,558,000 | $1,341,000 | $-2,198,000 |
| Change In Other Current Assets | $270,000 | $340,000 | $-1,987,000 | $-123,000 |
| Change In Payables And Accrued Expense | $-880,000 | $-5,310,000 | $4,370,000 | $1,716,000 |
| Change In Accrued Expense | $1,431,000 | $-3,969,000 | $1,270,000 | $-39,000 |
| Change In Payable | $-2,311,000 | $-1,341,000 | $3,100,000 | $1,755,000 |
| Change In Account Payable | $-2,311,000 | $-1,341,000 | $3,100,000 | $1,755,000 |
| Change In Prepaid Assets | $-1,674,000 | $-726,000 | $559,000 | $-28,000 |
| Change In Receivables | $727,000 | $-1,696,000 | $0 | - |
| Changes In Account Receivables | $727,000 | $-1,696,000 | $0 | - |
| Other Non Cash Items | $730,000 | $3,314,000 | $3,610,000 | $1,514,000 |
| Stock Based Compensation | $7,655,000 | $4,462,000 | $2,381,000 | $1,140,000 |
| Asset Impairment Charge | $30,886,000 | $0 | - | - |
| Amortization Of Securities | $-489,000 | $-1,782,000 | $-80,000 | $-145,000 |
| Depreciation Amortization Depletion | $4,280,000 | $3,565,000 | $3,630,000 | $2,511,000 |
| Depreciation And Amortization | $4,280,000 | $3,565,000 | $3,630,000 | $2,511,000 |
| Depreciation | $4,280,000 | $3,565,000 | $3,630,000 | $2,511,000 |
| Gain Loss On Sale Of PPE | $63,000 | $357,000 | $65,000 | $0 |
| Net Income From Continuing Operations | $-117,260,000 | $-83,581,000 | $-81,172,000 | $-58,032,000 |
| Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-25